Skip to search boxSkip to navigationSkip to main content

The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis

  • Maha Abdalla
    ,
  • Harika Sabbineni
    ,
  • Roshini Prakash
    ,
  • Adviye Ergul
    ,
  • Susan C. Fagan
    ,
  • Payaningal R. Somanath(corresponding author)
*Corresponding author for this work
  • University of Georgia
    ,
  • South College
    ,
  • ,
  • Medical College of Georgia
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Abstract

Background and Purpose Interstitial lung disease accounts for a group of chronic and progressive disorders associated with severe pulmonary vascular remodelling, peripheral vascular rarefaction and fibrosis, thus limiting lung function. We have previously shown that Akt is necessary for myofibroblast differentiation, a critical event in organ fibrosis. However, the contributory role of the Akt-mTOR pathway in interstitial lung disease and the therapeutic benefits of targeting Akt and mTOR remain unclear. Experimental Approach We investigated the role of the Akt-mTOR pathway and its downstream molecular mechanisms in chronic hypoxia- and TGFβ-induced pulmonary vascular pruning and fibrosis in mice. We also determined the therapeutic benefits of the Akt inhibitor triciribine and the mTOR inhibitor rapamycin for the treatment of pulmonary fibrosis in mice. Key Results Akt1-/- mice were protected from chronic hypoxia-induced peripheral vascular pruning. In contrast, hyperactivation of Akt1 induced focal fibrosis similar to TGFβ-induced fibrosis. Pharmacological inhibition of Akt, but not the Akt substrate mTOR, inhibited hypoxia- and TGFβ-induced pulmonary vascular rarefaction and fibrosis. Mechanistically, we found that Akt1 modulates pulmonary remodelling via regulation of thrombospondin1 (TSP1) expression. Hypoxic Akt1-/- mice lungs expressed less TSP1. Moreover, TSP1-/- mice were resistant to adMyrAkt1-induced pulmonary fibrosis. Conclusions and Implications Our study identified Akt1 as a novel target for the treatment of interstitial lung disease and provides preclinical data on the potential benefits of the Akt inhibitor triciribine for the treatment of interstitial lung disease.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 4173-4188 (16 pages)

Journal (Volume, Issue Number)

British Journal of Pharmacology (Volume 172, Issue 16)

Publication milestones

  • Published - 08/01/2015

Publication status

Published - 08/01/2015

ISSN

0007-1188

Publication IDs

  • Scopus: 84937521014
  • PubMed: 26033700

Publication metrics

Metrics

Scopus
citations
SciVal
FWCI
1.49
SciVal
Author count
6
SciVal
citations
30
SciVal
Paper percentile
89
Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
25
Mentions
5
Social media
74
Citation count
47

Funding Details

FundersFunding number
National Institutes of Health, National Cancer Institute
-
NHLBI
R01HL103952